Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Anti-inflammatory effects of targeted lung denervation in patients with COPD

Loes E.M. Kistemaker, Dirk-Jan Slebos, Herman Meurs, Huib A.M. Kerstjens, Reinoud Gosens
European Respiratory Journal 2015 46: 1489-1492; DOI: 10.1183/13993003.00413-2015
Loes E.M. Kistemaker
1Dept of Molecular Pharmacology, University of Groningen, Groningen, The Netherlands
2GRIAC Research Institute, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: l.e.m.kistemaker@rug.nl
Dirk-Jan Slebos
2GRIAC Research Institute, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
3University of Groningen, Dept of Respiratory Medicine, University Medical Center Groningen, Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Herman Meurs
1Dept of Molecular Pharmacology, University of Groningen, Groningen, The Netherlands
2GRIAC Research Institute, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Huib A.M. Kerstjens
2GRIAC Research Institute, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
3University of Groningen, Dept of Respiratory Medicine, University Medical Center Groningen, Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reinoud Gosens
1Dept of Molecular Pharmacology, University of Groningen, Groningen, The Netherlands
2GRIAC Research Institute, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Targeted lung denervation attenuates airway inflammation in patients with COPD http://ow.ly/QzLbD

To the Editor:

Acetylcholine is the primary parasympathetic neurotransmitter in the airways and induces bronchoconstriction via binding with M3 receptors. Cholinergic tone is increased in patients with chronic obstructive pulmonary disease (COPD) and this is the major reversible component of airflow obstruction in the disease [1]. Accordingly, treatment with anticholinergics is an effective bronchodilator therapy for patients with COPD [2]. Recent evidence from animal models of COPD revealed that acetylcholine also promotes airway inflammation and remodelling, which can be inhibited by anticholinergic intervention [3]. Such an anti-inflammatory effect of anticholinergic intervention could be clinically relevant. It has not been previously demonstrated in patients with COPD.

We investigated the effect of targeted lung denervation (TLD) on airway inflammation in COPD. TLD is a novel potential therapy for COPD, in which parasympathetic airway nerves are ablated by applying radiofrequency energy using a bronchoscopically guided catheter-based lung denervation system (Holaira, Inc., Plymouth, MN, USA) [4]. The lung denervation system includes a cooled electrode that is designed to generate therapeutic lesions at a sufficient depth from the inner surface of the main bronchus to ablate the airway nerves that travel parallel to and outside of the main bronchi and into the lungs. An expandable balloon provided protective cooling to minimise airway wall effects in the main bronchi during radiofrequency ablation of the nerves. Clinical evidence in COPD suggests that TLD improves lung function and quality of life [4]. We hypothesised that TLD would inhibit airway inflammation. Specifically, we studied whether TLD affects 1) inflammatory cell number and pro-inflammatory cytokine expression in bronchial wash fluid, and 2) gene expression of pro-inflammatory cytokines in bronchial brush specimens.

Patients with moderate-to-severe COPD were recruited as part of a safety and technical feasibility study for TLD (clinical trial number NCT01483534) [4]. Subjects recruited at the University Medical Center Groningen (Groningen, the Netherlands) (n=7, two males, age 56±10 years, smoking history 36±14 pack-years, forced expiratory volume in 1 s (FEV1) 27.6±6.7% predicted and 0.70±0.13 L, forced vital capacity (FVC) 2.19±0.27 L; all mean±sd, pre-bronchodilator FEV1 and FVC) were included in the sub-study investigating the effects of TLD on inflammation. Patients used oral corticosteroids during the interventions, and there was no additional use of anti-inflammatory medication. Patients were allowed to use their regular medication. TLD of the right lung was performed on day 0. A bronchial wash (two times 25 mL of saline) and brush were collected from the lung distal to the site of denervation before (day 0) and after denervation (day 30). On the bronchial wash, a differential cell count was performed on cytospin preparations stained for May–Grünwald and Giemsa (both from Sigma, St Louis, MO, USA) by counting 400 cells in duplicate in a blinded fashion. Cytokine concentrations in the wash were determined using a multiplex assay (26-plex; Millipore, Billerica, MA, USA). The following cytokines were measured: C-C chemokines CCL2, CCL4 and CCL11, C-X-C chemokines CXCL8 and CXCL10, granulocyte colony-stimulating factor (CSF), interferon (IFN)-α2, interleukin (IL)-6 and IL-7. The following cytokines were below the detection limit of 3.2 pg·mL−1: granulocyte-macrophage CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, macrophage inflammatory protein (MIP)-1α, tumour necrosis factor (TNF)-α and TNF-β. From the bronchial brush, total RNA was extracted (Qiagen, Venlo, the Netherlands), reverse transcribed and subjected to quantitative reverse transcriptase PCR to analyse gene expression levels of CXCL8, IL-6, transforming growth factor (TGF)-β and mucin MUC5AC using 18S as a reference gene. Comparisons between day 0 and day 30 were performed using a Wilcoxon signed rank test and differences were considered statistically significant at p<0.05.

The results are presented in figure 1, where the relative change at day 30 compared with day 0 in levels of neutrophils and protein expression of CXCL8 (IL-8) and CCL4 (MIP-1β) in the bronchial wash, and the relative change in gene expression of CXCL8, IL-6, TGF-β and MUC5AC in the bronchial brush is depicted. For the seven patients studied, the percentage of neutrophils in the bronchial wash was decreased after TLD in five patients, CXCL8 decreased in four patients and CCL4 decreased in six patients (p=0.047). Gene expression of CXCL8 in the brush decreased in six patients (p=0.031), as did IL-6 in five patients, TGF-β in six patients (p=0.047) and MUC5AC in five patients. No significant change in the number of macrophages, lymphocytes, eosinophils and the additional cytokines was observed. In this small study population, a repeated measures ANCOVA did not show significant interactions of these parameters with changes in clinical parameters, including FEV1, in response to TLD.

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Percentage change at day 30 compared with day 0 in levels of neutrophils and protein expression of the C-X-C chemokine CXCL8 (also known as interleukin (IL)-8) and the C-C chemokine CCL4 (also known as macrophage inflammatory protein-1β) in bronchial wash, and in gene expression of CXCL8, IL-6, transforming growth factor (TGF)-β and mucin MUC5AC in bronchial brush. Baseline values are set to 100%, represented by the dotted line. The horizontal lines represent the median. *: p<0.05 (Wilcoxon signed rank test).

Our findings suggest that TLD attenuates airway inflammation. Evidence from patients on the role of acetylcholine in inflammation is limited. Although the use of tiotropium bromide is associated with a reduction in exacerbation frequency [2], methodological problems have hampered the evaluation of inflammation in the available drug study [5]. This bronchoscopic targeting of the parasympathetic system enabled us to examine the effects on airway inflammation in a completely novel, direct manner. Pre-clinical studies using sheep models have demonstrated effective destruction of cholinergic airway nerves by this device [6]. Although denervation also targets sensory nerve fibres that release pro-inflammatory neuropeptides, such as substance P and calcitonin gene-related peptide, these nerves have been shown to regenerate in the sheep model, in contrast to cholinergic nerve fibres. We cannot verify the impact of the TLD treatment on individual nerve fibres and mediators in the patients in the current study; therefore, it is important to stress that whereas we believe that these findings suggest a pro-inflammatory role for acetylcholine in the airways, the involvement of additional neurotransmitters and neuropeptides cannot be excluded. In addition, there might be subtle changes in bronchial vessels that could contribute to leukocyte supply, although TLD in sheep did not result in a discernible change in bronchial vessel number or calibre distal to the treatment site. Therefore, we propose that this anti-inflammatory effect of TLD is mediated via inhibition of acetylcholine release.

A pro-inflammatory role for acetylcholine has already been proposed from animal models of COPD [3]. It has been shown that lipopolysaccharide-induced and cigarette smoke-induced inflammation and remodelling can be inhibited by anticholinergic treatment or by knock-out of the muscarinic M3 receptor [7, 8].

Acetylcholine is not only a neurotransmitter but is also produced by non-neuronal cells. It has been proposed that this non-neuronal acetylcholine is responsible for the pro-inflammatory effects of acetylcholine [9, 10]. The current study suggests that neuronal acetylcholine may in fact contribute to inflammation in COPD.

Furthermore, TLD might also have effects on airway remodelling, since a significant reduction in TGF-β was observed. This aligns well with the reduction in TGF-β we have previously found in muscarinic M3 receptor knock-out mice [8], and with the human data from the UPLIFT (Understanding Potential Long-term Impacts on Function with Tiotropium) trial, where tiotropium reduced lung function decline in a subgroup of patients [11].

There are limitations to this small cohort pilot study, including the limited number of subjects and the lack of control of successful denervation. However, we believe that the findings are promising, and a large-scale multicentre sham-controlled study of the effectiveness of TLD is planned and will include similar analyses. This should provide more evidence for the role of neuronal acetylcholine as a pro-inflammatory mediator. Moreover, it would be interesting to perform similar analyses in patients treated with anticholinergic drugs. Whether anticholinergic intervention will become a tool to treat inflammation is a question to be confirmed in the future.

In conclusion, our findings constitute explorative evidence for a role of TLD in inhibition of inflammation in patients with COPD. This is of clinical interest because current anti-inflammatory therapy, including corticosteroids, is of limited effectiveness. This is a novel and sparsely explored intervention that might affect treatment strategy in COPD in the future.

Footnotes

  • Support statement: Financial support was received from the Netherlands Lung Foundation, grant number 3.2.08.014; and from Holaira, Inc., Plymouth, MN, USA.

  • Conflict of interest: Disclosures can be found alongside the online version of this article at erj.ersjournals.com

  • Received March 13, 2015.
  • Accepted July 2, 2015.
  • Copyright ©ERS 2015

References

  1. ↵
    1. Gross NJ,
    2. Skorodin MS
    . Role of the parasympathetic system in airway obstruction due to emphysema. N Engl J Med 1984; 311: 421–425.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Tashkin DP,
    2. Celli B,
    3. Senn S, et al.
    A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543–1554.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Kistemaker LE,
    2. Gosens R
    . Acetylcholine beyond bronchoconstriction: roles in inflammation and remodeling. Trends Pharmacol Sci 2015; 36: 164–171.
    OpenUrlCrossRef
  4. ↵
    1. Slebos DJ,
    2. Klooster K,
    3. Koegelenberg CF, et al.
    Targeted lung denervation for moderate to severe COPD: a pilot study. Thorax 2015; 70: 411–419.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Powrie DJ,
    2. Wilkinson TM,
    3. Donaldson GC, et al.
    Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 2007; 30: 472–478.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Mayse M,
    2. Johnson P,
    3. Streeter J, et al.
    Targeted lung denervation in the healthy sheep model – a potential treatment for COPD. Eur Respir J 2014; 44: Suppl. 58, P943.
    OpenUrl
  7. ↵
    1. Pera T,
    2. Zuidhof A,
    3. Valadas J, et al.
    Tiotropium inhibits pulmonary inflammation and remodelling in a guinea pig model of COPD. Eur Respir J 2011; 38: 789–796.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Kistemaker LE,
    2. Bos IS,
    3. Hylkema MN, et al.
    Muscarinic receptor subtype-specific effects on cigarette smoke-induced inflammation in mice. Eur Respir J 2013; 42: 1677–1688.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Gwilt CR,
    2. Donnelly LE,
    3. Rogers DF
    . The non-neuronal cholinergic system in the airways: an unappreciated regulatory role in pulmonary inflammation? Pharmacol Ther 2007; 115: 208–222.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Kistemaker LE,
    2. Oenema TA,
    3. Meurs H, et al.
    Regulation of airway inflammation and remodeling by muscarinic receptors: perspectives on anticholinergic therapy in asthma and COPD. Life Sci 2012; 91: 1126–1133.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Morice AH,
    2. Celli B,
    3. Kesten S, et al.
    COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT). Respir Med 2010; 104: 1659–1667.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 46 Issue 5 Table of Contents
European Respiratory Journal: 46 (5)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Anti-inflammatory effects of targeted lung denervation in patients with COPD
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Anti-inflammatory effects of targeted lung denervation in patients with COPD
Loes E.M. Kistemaker, Dirk-Jan Slebos, Herman Meurs, Huib A.M. Kerstjens, Reinoud Gosens
European Respiratory Journal Nov 2015, 46 (5) 1489-1492; DOI: 10.1183/13993003.00413-2015

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Anti-inflammatory effects of targeted lung denervation in patients with COPD
Loes E.M. Kistemaker, Dirk-Jan Slebos, Herman Meurs, Huib A.M. Kerstjens, Reinoud Gosens
European Respiratory Journal Nov 2015, 46 (5) 1489-1492; DOI: 10.1183/13993003.00413-2015
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • COPD and smoking
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Airway immune responses to COVID-19 vaccination in COPD patients
  • Wider access to rifapentine-based regimens is needed for TB care globally
  • Association between immunosuppressants and outcomes of COVID-19
Show more Agora

Research letters

  • Mitochondrial DNA as biomarker of survival in RA-ILD
  • Lung transplantation for cystic fibrosis before and after availability of elexacaftor/tezacaftor/ivacaftor
  • Elexacaftor-tezacaftor-ivacaftor and circulating neutrophil counts in CF
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society